文献速递骨软组织肉瘤与黑色素瘤

恩考拉非尼联合比美替尼后接伊匹木单抗和纳武利尤单抗对比伊匹木单抗和纳武利尤单抗治疗BRAFV600E或BRAFV600K突变晚期黑色素瘤患者(EBIN):一项国际、开放标签、随机、对照、2期研究

Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.
PubMed 文献 · Lancet Oncol · 2025-01-01

EBIN是一项在8个欧洲国家37个中心开展的开放标签、随机、对照2期试验,纳入271例既往未治疗、不可切除的III期或IV期BRAFV600E或BRAFV600K突变黑色素瘤患者,按1:1随机分为靶向治疗诱导组(恩考拉非尼450 mg每日一次+比美替尼45 mg每日两次,共12周,随后纳武利尤单抗3 mg/kg+伊匹木单抗1 mg/kg每3周一次共4次,随后纳武利尤单抗480 mg每4周一次)和对照组(单纯上述免疫检查点抑制剂治疗)。诱导组与对照组中位无进展生存期均为9个月,无进展生存期延长的证据不成立(HR 0.87,90%CI 0.67-1.12;p=0.36)。

要点

  • 诱导组与对照组中位无进展生存期均为9个月,HR 0.87(90%CI 0.67-1.12;p=0.36),无进展生存期延长的证据不成立。
  • 诱导组3-5级治疗相关不良事件57例(42%,136例中),对照组42例(32%,131例中)。
  • 诱导组发生2例治疗相关死亡(心脏事件:心力衰竭和心律失常),对照组1例(脑膜炎)。

核心结论

  • 在未经选择的BRAFV600E或BRAFV600K突变晚期黑色素瘤患者中,靶向治疗诱导方案与一线免疫检查点抑制剂治疗相比未改善无进展生存期。

研究设计与样本

  • 开放标签、随机、对照、2期试验(EBIN),在8个欧洲国家的37个中心开展。
  • 纳入18岁及以上、既往未治疗、不可切除的III期或IV期BRAFV600E或BRAFV600K突变黑色素瘤患者,ECOG体力状态为0或1。
  • 2018年11月12日至2022年7月11日共随机271例:诱导组136例,对照组135例;103例(38%)女性,168例(62%)男性,中位年龄55岁(IQR 43-66)。
  • 采用最小化技术随机,按中心和基于分期与乳酸脱氢酶活性定义的变量分层;主要结局为意向治疗人群的无进展生存期。
  • 中位随访时间21个月(IQR 13-33)。

主要发现

  • 诱导组与对照组相比无进展生存期延长的证据不成立(HR 0.87,90%CI 0.67-1.12;p=0.36)。
  • 中位无进展生存期诱导组9个月(95%CI 7-13),对照组9个月(95%CI 5-14)。
  • 3-5级治疗相关不良事件:诱导组开始治疗的136例中57例(42%),对照组开始治疗的131例中42例(32%)。
  • 最常见的3-4级治疗相关不良事件为肝炎:诱导组136例中17例(13%),对照组131例中9例(7%)。
  • 严重治疗相关不良事件:诱导组136例中45例(33%),对照组131例中33例(25%);治疗相关死亡3例,诱导组2例(心脏事件:心力衰竭和心律失常),对照组1例(脑膜炎)。

关键数值与推荐

  • 诱导组方案:口服恩考拉非尼450 mg每日一次+口服比美替尼45 mg每日两次,共12周;随后静脉纳武利尤单抗3 mg/kg+静脉伊匹木单抗1 mg/kg每3周一次共4次,随后静脉纳武利尤单抗480 mg每4周一次,直至不可接受毒性、疾病进展或治疗满2年。
  • 对照组方案:上述免疫检查点抑制剂治疗,不接受诱导靶向治疗。
  • 主要结局为意向治疗人群的无进展生存期;安全性在全部开始方案治疗的患者中评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current first-line treatment for patients with metastatic melanoma with BRAFV600E or BRAFV600K mutations includes immunotherapy with immune checkpoint inhibitors and targeted therapy; however, the optimal sequencing of these treatments is unclear. We aimed to investigate the use of a targeted-therapy induction regimen before treatment with immune checkpoint inhibitors. METHODS: This open-label, randomised, controlled, phase 2 trial (EBIN) was conducted at 37 centres in eight European countries. Eligible patients were 18 years or older and had previously untreated, unresectable, stage III or IV melanoma with BRAFV600E or BRAFV600K mutations and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) to one of two groups. Those in the induction group received targeted therapy (oral encorafenib 450 mg once a day plus oral binimetinib 45 mg twice a day for 12 weeks) followed by immune checkpoint inhibitors (intravenous nivolumab 3 mg/kg plus intravenous ipilimumab 1 mg/kg once every 3 weeks for four doses, followed by intravenous nivolumab 480 mg once every 4 weeks until unacceptable toxicity, disease progression, or 2 years of treatment). Patients in the control group received immune checkpoint inhibitors as above without any induction targeted therapy. Randomisation was conducted using a minimisation technique and was stratified by centre and a variable defined using stage and lactate dehydrogenase activity. The primary outcome was progression-free survival in the intention-to-treat population. Safety was assessed in all patients who initiated the protocol treatment. In this Article we report the primary analysis. The study is registered with ClinicalTrials.gov, NCT03235245, and is ongoing. FINDINGS: Between Nov 12, 2018, and July 11, 2022, 271 patients were randomly assigned: 136 to the induction group and 135 to the control group. 103 (38%) patients were female, 168 (62%) were male, and the median age was 55 years (IQR 43-66). The median follow-up time was 21 months (IQR 13-33). There was no evidence of a longer progression-free survival in the induction group than in the control group (hazard ratio 0·87, 90% CI 0·67-1·12; p=0·36). The median progression-free survival was 9 months (95% CI 7-13) in the induction group and 9 months (5-14) in the control group. Grade 3-5 treatment-related adverse events occurred in 57 (42%) of 136 patients who started treatment in the induction group and in 42 (32%) of 131 patients who started treatment in the control group. The most common grade 3-4 treatment-related adverse event was hepatitis (17 [13%] of 136 patients in the induction group and nine [7%] of 131 patients in the control group). Serious treatment-related adverse events occurred in 45 (33%) of 136 patients in the induction group and 33 (25%) of 131 patients in the control group. There were three treatment-related deaths: two from cardiac events (heart failure and arrhythmia) in the induction group and one from meningitis in the control group. INTERPRETATION: The targeted-therapy induction regimen did not improve progression-free survival compared with first-line treatment with immune checkpoint inhibitors in unselected patients with advanced melanoma with BRAFV600E or BRAFV600K mutations. FUNDING: Bristol Myers Squibb and Pierre Fabre.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Robert C, Kicinski M, Dutriaux C, et al. Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2025. PMID: 40449497. doi:10.1016/S1470-2045(25)00133-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。